Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance - Wu, Wei; Klockow, Jessica L.; Zhang, Michael; Lafortune, Famyrah; Chang, Edwin; Jin, Linchun; Wu, Yang; Daldrup-Link, Heike E. (Pharmacological research, 2021)
Keywords: Animals; Antineoplastic Agents - therapeutic use; Brain Neoplasms - drug therapy; Chemotherapy; Drug Resistance, Neoplasm; Glioblastoma; Glioblastoma - drug therapy; Humans; Immunotherapy; Nanotherapy; Radiotherapy; Targeted therapy; Lomustine (PubChem CID: 3950); Targeted therapy; Glioblastoma; Niraparib (PubChem CID: 24958200); Radiotherapy; Nanotherapy; Erlotinib (PubChem CID: 176870); Temozolomide (PubChem CID: 5394); Chemotherapy; Veliparib (PubChem CID: 11960529); Carmustine (PubChem CID: 2578); Immunotherapy; Irinotecan (PubChem CID: 60838); Cediranib (PubChem CID: 9933475); Gefitinib (PubChem CID: 123631); Olaparib (PubChem CID: 23725625)